Speaker(s)

Title	First name	Last name	City	Country
NGS-based MRD technology: a specific tool for prospective MRD monitoring	Jan	Trka	Prague	Czech Republic
How to measure MRD in the era of targeted treatment	Monika	Brüggemann	Kiel	Germany
Improved outcome by better risk group definition in childhood ALL: comparison between Dutch and BFM approaches in treatment reduction	Rob	Pieters	Utrecht	Netherlands
ALL together: integrated risk stratification in ALL: response and genetics	John	Moppett	Bristol	Great Britain
Adult ALL: how to use MRD measurements for stratification of new treatment modalities	Joseph Maria	Ribera	Bandalona	Spain
Introduction on MRD in AML: what can we learn from ALL?	Oliver	Ottmann	Cardiff	Great Britain
Molecular MRD detection: Technical overview in AML and its clinical application	Adam	Ivey	Melbourne	Australia
Flowcytometric MRD detection: the myeloid stem cell/AML stem cell approach	Gerrit Jan	Schuurhuis	Amsterdam	The Netherlands
How to implement MRD detection in clinical AML trials	Konstanze	Döhner	Ulm	Germany
New response	Brian	Durie	Los Angelos	United States

criteria in multiple myeloma: how to integrate complementary MRD approaches				
Heavy-light chain monitoring in plasma vs flow MRD in the BM in MM	Ruth	De Tute	Leeds	Great Britain
Clinical impact of MRD by conventional flow vs NGF in MM	Bruno	Paiva	Pamplona	Spain
MRD trials in mature lymphoid malignancies	Marco	Ladetto	Alessandria	Italy
Use of cell-free tumor DNA (ctDNA) in plasma or cellular DNA from BM and/or PB: which strategy for tissue-born lymphomas	Davide	Rossi	Bellinzona	Italy
Occult CNS involvement by flow cytometry in aggressive lymphoma	Alberto	Orfao	Salamanca	Spain
Meaning of MRD detection in treatment of lymphoma/CLL with new drugs	Paolo	Ghia	Milano	Italy
Immune-monitoring in addition to MRD monitoring	Jacques J.M.	Van Dongen	Leiden	The Netherlands
CD19 targeted therapies: impact on normal and malignant cells	Claudia	Rössig	Münster	Germany